Volume 28, Number 8—August 2022
Research
Invasive Pneumococcal Disease and Long-Term Mortality Rates in Adults, Alberta, Canada
Kristen A. Versluys, Dean T. Eurich
, Thomas J. Marrie, and Gregory J. Tyrrell
, Thomas J. Marrie, and Gregory J. Tyrrell
Table 1
Characteristics for case-patients and controls for invasive pneumococcal disease long-term mortality rates in adults, Alberta, Canada*
| Characteristic | Case-patients | Controls |
|---|---|---|
| Total |
4,522 (100.0) |
8,837 (100.0) |
| Sex | ||
| M | 2,565 (56.7) | 4,994 (56.5) |
| F |
1,957 (43.3) |
3,843 (43.5) |
| Age, y | ||
| <45 | 1,324 (29.3) | 2,579 (29.2) |
| 45‒60 | 1,388 (30.7) | 2,735 (30.9) |
| 60‒75 | 1,054 (23.3) | 2,060 (23.3) |
| >75 | 756 (16.7) | 1,463 (16.6) |
| Mean age, y (+SD) |
55.8 (17.7) |
55.8 (17.7) |
| Type of IPD | ||
| Pneumonia | 2,008 (44.4) | |
| Positive blood culture | 1,961 (97.7) | |
| Positive pleural fluid | 16 (0.8) | |
| Positive pericardial fluid | 3 (0.1) | |
| Positive peritoneal fluid | 2 (0.1) | |
| Unknown | 26 (1.3) | |
| Meningitis | 116 (2.6) | |
| Bacteremia/sepsis | 2,315 (51.2) | |
| Unspecified type | 646 (14.3) | |
| Unknown |
1,496 (33.0) |
|
| Median comorbidity score (IQR) |
5 (2‒9) |
5 (2‒8) |
| Comorbidities | ||
| Asplenia | 25 (0.6) | 22 (0.5) |
| Solid organ transplant | 113 (2.5) | 187 (4.2) |
| HIV infection | 136 (3.0) | 41 (0.9) |
| Other immunosuppression conditions† | 1,456 (32.2) | 2,252 (50.0) |
| Malignancies | 1,052 (23.3) | 1,889 (41.9) |
| Chronic obstructive pulmonary disease | 1,193 (26.4) | 1,469 (32.6) |
| Other respiratory diseases‡ | 771 (17.1) | 1,139 (25.3) |
| Asthma | 1,045 (23.1) | 1,506 (33.4) |
| Chronic renal disease | 502 (11.1) | 881 (19.6) |
| Hypertension | 1,790 (39.6) | 2,744 (60.9) |
| Ischemic heart disease | 990 (21.9) | 1,925 (42.7) |
| Arrhythmias | 1,662 (36.8) | 2,785 (61.8) |
| Valvular heart disease | 244 (54.0) | 512 (11.4) |
| Congestive heart failure | 645 (14.3) | 1,207 (26.8) |
| Chronic liver disease | 806 (17.8) | 863 (19.2) |
| Diabetes | 1,057 (23.4) | 1,768 (39.2) |
| Smoking | 907 (20.1) | 1,136 (25.2) |
| Harmful alcohol use§ | 1,968 (43.5) | 2,503 (55.6) |
*Values are no. (%) except as indicated. †Neutropenia, leukopenia, leukocyte disease, functional and genetic leukocyte cell abnormalities, myelofibrosis, disorders of immune mechanism. ‡Acute bronchitis, pneumoconiosis, pneumonitis, pulmonary embolism, and other pulmonary circulation disorders. §Alcohol related disorders, toxic effects of alcohol, alcoholic polyneuropathy, alcoholic cardiomyopathy, alcoholic gastritis, alcoholic fatty liver disease, alcoholic cirrhosis, alcoholic liver disease, alcohol abuse counseling and surveillance.
Page created: July 11, 2022
Page updated: July 20, 2022
Page reviewed: July 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.